Improving healthspan and lifespan by innovating therapeutic care.
Willow Laboratories, formerly Cercacor Laboratories, was founded in 1998 by Joe Kiani. Here we developed Rainbow® Technology, the patented multi-wavelength optical platform for noninvasive measurement now used in leading hospitals worldwide.
Today we are a health innovation company headquartered in Irvine, California, taking on the diabetes and metabolic-health crisis with medical devices and digital solutions: Nutu, a digital lifestyle program, and Ember, a multi-parameter health tracker.
- 1998Founded by Joe Kiani as Cercacor Laboratories.
- 2005Rainbow® Technology launches, going on to monitor millions of patients each year.
- TodayNow Willow Laboratories: Nutu and Ember bring our science to everyday metabolic health and prevention.
How we work.
- 01
Remain faithful to your promises and responsibilities.
- 02
Thrive on fascination and accomplishment, not greed and power.
- 03
Make each year better than the last, personally and as a team.
- 04
Make each day as fun as possible.
- 05
Do what is best for patient care.
Decades of medical-device experience, focused on prevention.
Joe Kiani is the Founder and Executive Chairman of Willow Laboratories, a health and wellness innovator dedicated to advancing noninvasive monitoring solutions and reinventing diabetes care. Prior to Willow, Kiani founded Masimo in 1989 and led it from a garage startup to a publicly traded medical technology company with over $2 billion in revenue. He holds more than 600 patents and co-invented measure-through-motion pulse oximetry. His technology is used to monitor over 200 million patients annually. He also founded the Patient Safety Movement Foundation to help eliminate preventable hospital deaths.
Kiani is co-founder and CEO of Like Minded Labs, a media technology company reimagining virtual collaboration. In addition, he serves as Chairman of Clarity, a breast cancer-focused medtech company, and SMS Biotech, which is democratizing adult stem cell technologies for human health, and is an investor and board member at CDX Medical Technologies (a pioneer in ECMO pump innovation), MY01 (transforming diagnosis of limb perfusion injuries), and IRAMED (a leader in MRI-compatible patient monitoring and infusion systems).
Mohamed Diab is an accomplished technology leader in the medical device field, bringing decades of expertise in non-invasive sensing and physiological monitoring to guide Willow Laboratories’ research, development, and product innovation. With an extensive patent portfolio spanning multi-wavelength sensors, alarm systems, and advanced non-invasive analytical devices, he leads cross-functional teams in engineering, product design, and regulatory strategy. A graduate of California State University, Fullerton, Diab previously held senior technical leadership roles at Masimo Corporation. As CTO, he advances Willow’s mission to deliver breakthrough medical technologies that enhance patient care and extend healthspan through safety, accuracy, and scalability.
Tao Levy joined the company in 2025 as Chief Financial Officer, overseeing all financial and administrative operations. With extensive experience in financial services and the medical device industry, he plays a key role in supporting the company’s growth strategy. Before joining, Tao served as Executive Vice President of Business Development at Masimo Corporation, a publicly traded medical device manufacturer, where he was part of the executive management team. In this role, he led inorganic growth initiatives, including M&A, partnerships, licensing agreements, and investments. He also brings over a decade of experience as a Senior Equity Research Analyst covering the medical devices sector at various firms, including Deutsche Bank and Wedbush Securities. Tao holds a B.A. in Biology from the University of Pennsylvania.
Nicole Campagna joined Willow Laboratories in November 2025, bringing more than 15 years of experience in commercial strategy, B2B growth, and client success across the digital health and medical-device sectors. She has a proven track record of building and scaling enterprise partnerships, developing high-performing teams, and driving population-health outcomes for employers, payers, and health systems.
Nicole began her career in M&A at Philips Respironics, working across medical-device acquisitions and building a strong foundation in product, market, and deal strategy. She later spent more than a decade at WeightWatchers, where she built and scaled the company’s B2B business from the ground up—leading employer and payer partnerships, commercial strategy, and client-success operations focused on weight health and chronic-condition prevention.
At Willow Laboratories, Nicole leads commercialization and strategy for Nutu — a solution designed to help prevent type 2 diabetes, improve weight health, and support payers and employers in driving meaningful population-health outcomes.
Diane Perez joined Willow Laboratories in November 2024 as Vice President of Business Development, bringing over 25 years of experience in medical communication, strategic clinical collaboration, and business expansion. A medical doctor, Diane has been a prominent health communicator in international media, educating audiences on health and wellness through trusted, accessible content. She has hosted medical TV shows and participates in several media outlets, providing expert advice on healthy living. Dr. Perez has been a major contributor to advancing health initiatives and legislative changes for critical newborn health screenings in Mexico. As an accomplished author, she has published two books with Penguin Random House on 200 diseases and a healthy lifestyle to lose weight. Diane earned her medical degree from the National Autonomous University of Mexico (UNAM) and a Master of Healthcare Management from the Harvard School of Public Health.
With over 30 years of experience in biotech, medical devices, advertising, supply chain, and production studios, Roger Wu combines strategic vision with hands-on expertise to deliver impactful solutions. As Vice President of Creative Services, he has a proven track record of developing branding, marketing, and design strategies that enhance engagement and drive business growth. A holder of multiple design patents, Roger excels at transforming complex ideas into compelling visual solutions, fostering innovation, and leading cross-industry collaboration.
Mike joined Willow Labs in November 2024, bringing more than 30 years of global manufacturing and operations experience in the medical device industry with a proven track record of executing and delivering new products while optimizing product cost and supply chains on legacy products. Mike has successfully built and led supply chain, manufacturing, and sustaining engineering teams to bring new products to market, expanding product portfolios and operations capabilities aligned with growth objectives. Mike will oversee the development and scaling of Willow’s Manufacturing Team and Global Operations. Mike holds a B.S. in Mechanical Engineering from San Diego State University.
Marty Wexler joined Willow Laboratories in March 2025 as Vice President of Sales and National Accounts, bringing over 40 years of expertise in sales, sales management, and corporate account leadership. Before joining Willow, Marty held multiple leadership roles at Masimo, most recently serving as Senior Director of Corporate Accounts. In this role, he played a pivotal role in converting major health systems and IDNs to Masimo technologies, leveraging his expertise in product launches, market strategy development, and contract negotiations. His tenure at Masimo also included key positions in sales management, strategic account management, and corporate account leadership. Earlier in his career, Marty served as Vice President of Sales at LifeSync Corporation and held various sales management roles in other medical device companies. Throughout his career, he has consistently driven business growth and profitability in multi-million-dollar markets, applying his deep industry knowledge and strategic sales approach.
Vincent Schneider joined the company in September 2025 as International Vice President, Business Development & Sales, overseeing our operations outside the United States. With more than 30 years of international leadership experience across Healthcare, Medical Devices, Computer Science, and Luxury Brands, Vincent has successfully led major transformation initiatives in both high-growth and underperforming environments. His expertise spans mergers and acquisitions, post-merger integration, and global business expansion. Prior to joining the company, Vincent served as Vice President of Strategic OEM Business Development at Masimo Corporation, a publicly traded leader in medical technology.
Our board.
Joe KianiExecutive Chairman
Joe Kiani is the Founder and Executive Chairman of Willow Laboratories, a health and wellness innovator dedicated to advancing noninvasive monitoring solutions and reinventing diabetes care. Prior to Willow, Kiani founded Masimo in 1989 and led it from a garage startup to a publicly traded medical technology company with over $2 billion in revenue. He holds more than 600 patents and co-invented measure-through-motion pulse oximetry. His technology is used to monitor over 200 million patients annually. He also founded the Patient Safety Movement Foundation to help eliminate preventable hospital deaths.
Kiani is co-founder and CEO of Like Minded Labs, a media technology company reimagining virtual collaboration. In addition, he serves as Chairman of Clarity, a breast cancer-focused medtech company, and SMS Biotech, which is democratizing adult stem cell technologies for human health, and is an investor and board member at CDX Medical Technologies (a pioneer in ECMO pump innovation), MY01 (transforming diagnosis of limb perfusion injuries), and IRAMED (a leader in MRI-compatible patient monitoring and infusion systems).
Dr. Jill Biden, Ed.D.Board Member
Dr. Jill Biden is an American educator, author, and former First Lady of the United States. She has spent much of her life in the classroom, teaching English, writing, and reading at the high school and community college levels. She earned a Doctor of Education degree from the University of Delaware, reflecting her deep commitment to teaching and student success.
Throughout her public life, Dr. Biden has been a strong advocate for education, community colleges, military families, and expanded opportunities for women and children. As Second Lady and later First Lady of the United States, she continued teaching while also using her platform to support students, educators, service members, veterans, and working families. Known for balancing public service with her career as an educator, Dr. Biden has emphasized the importance of compassion, resilience, and lifelong learning.
In addition to her work in education, Dr. Biden has been an active advocate for healthcare causes, particularly cancer prevention, early detection, and women’s health. Her advocacy began with the Biden Breast Health Initiative, which educated young women about breast health and cancer awareness. As First Lady, she continued this work through the Cancer Moonshot initiative, supporting efforts to improve cancer screening, patient navigation, and family-centered care. She has also championed women’s health research, helping bring national attention and federal investment to areas of medicine that have historically been underfunded.
Ken BuckBoard Member
Ken Buck graduated from Princeton University in 1981 and the University of Wyoming Law School in 1985. After law school, Ken worked for Congressman Dick Cheney (R-WY) on the Iran-Contra Investigation and then became a prosecutor with the U.S. Department of Justice. In 1990, Ken joined the Colorado U.S. Attorney’s Office where he became the Chief of the Criminal Division. During his tenure as a federal prosecutor, Ken taught as an Adjunct Law Professor.
Mohamed DiabBoard Member & CTO
Mohamed Diab is an accomplished technology leader in the medical device field, bringing decades of expertise in non-invasive sensing and physiological monitoring to guide Willow Laboratories’ research, development, and product innovation. With an extensive patent portfolio spanning multi-wavelength sensors, alarm systems, and advanced non-invasive analytical devices, he leads cross-functional teams in engineering, product design, and regulatory strategy. A graduate of California State University, Fullerton, Diab previously held senior technical leadership roles at Masimo Corporation. As CTO, he advances Willow’s mission to deliver breakthrough medical technologies that enhance patient care and extend healthspan through safety, accuracy, and scalability.
Said HilalBoard Member
Said Hilal has been President and CEO of Applied Medical since the company’s inception in 1987. As a new generation medical device company, Applied Medical utilizes innovation in design, development and processes to enhance clinical outcomes while reducing the cost of healthcare.
Said Hilal holds an MBA from the University of Southern California, and MS and BS degrees in Mechanical Engineering from California State University, Long Beach. He received CSULB’s Distinguished Alumnus Award in 1996 and the Honorary Degree of Doctor of Humane Letters in 2023.
Sarah KianiBoard Member
Sarah Kiani is a dedicated global advocate for health equity, patient safety, environmental stewardship, and community well-being. With a deep commitment to advancing health outcomes for people, animals, and the planet, Sarah has championed initiatives that reflect both compassion and impact.
Parag SaxenaBoard Member
Parag Saxena is a Founding General Partner and CEO of New Silk Partners, a USD 1.383 billion fund founded in 2007 focused on making investments in India and the sub-continent. He also co-founded Vedanta Capital LLC, a U.S. venture capital firm founded in 2006. Previously, he was CEO of INVESCO Private Capital, one of the world’s oldest and largest independent asset management companies. During the course of his 23-year tenure at INVESCO, the firm and its predecessors made over 300 investments, including Amgen, Costco, PictureTel, Polycom, Staples and Starbucks. He was responsible for both direct and fund of funds investment activities where he led over $8 billion in peak assets. At INVESCO Private Capital, he led over 90 investments, a third of which went on to become public companies. These include Alkermes, Celgene, Genomic Health, Indigo, Masimo, Transgenomic, Xenon Pharmaceuticals, Amber Networks, ARM Holdings, MetroPCS and Volterra.
Help build the future of therapeutic care.
We are always looking for exceptional engineers to join a team that values creativity and collaboration.
Our offices
UC Irvine Research ParkVancouver, Canada910 Richards St
Vancouver, BC V6B 3C1